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In this issue of the Polish Journal of Neurology and Neu-
rosurgery, Żur-Wyrozumska, et al. describes the very first 
genetically proven case of CSF1R-related leukoencephalopathy 
in Poland [1]. CSF1R-related leukoencephalopathy (due to 
mutations in CSF1R gene [2]) has been reported in multiple 
countries around the world (reviewed in Konno, et al. [3]); 
however, despite its worldwide occurrence, CSF1R-related 
leukoencephalopathy is still an underdiagnosed condition [4].
There are three primary reasons for this diagnostic dif-
ficulty. The disease was first recognized by Van Bogaert and 
Nyssen back in 1936 [5] as a subset of orthochromatic leuko-
dystrophies. They identified it as a pigmentary orthochromatic 
leukodystrophy (POLD). However, until the discovery of 
causative CSF1R gene mutations in 2011 [2], only a handful of 
sporadic and familiar POLD cases were published (reviewed in 
Marotti, et al. [6]). To diagnose it with certainty, either brain 
biopsy or autopsy had to be done.  
The second reason relates to a nomenclature confusion 
leading to labeling many cases of POLD as hereditary diffuse 
leukoencephalopathy with spheroids (HDLS). For example, in 
our own first publication on this subject from 2006, we erro-
neously named a POLD family as an HDLS family [7]. HDLS 
was first describe by Axelsson et al in 1984 [8] in a Swedish 
family with clinical and pathologic similarities to POLD 
families. Recently, this family was found to carry mutations in 
AARS2 gene [9]. Even before this genetic discovery, we found 
that families mislabeled as HDLS were indeed POLD families 
[10]. Fortunately, these nomenclature difficulties stemming 
from similarities in clinical and pathologic presentations have 
been solved by advances in genetic technology. The nomen-
clature introduced by Konno et al. [3] simplifies it, and now 
we identify these two separate conditions as CSF1R-related 
leukoencephalopathy, formerly POLD families, and AARS2- 
-related leukoencephalopathy, formerly HDLS families (Tab. 1). 
Unfortunately, there are also published and unpublished cases/
/families suspected for CSF1R-related leukoencephalopathy
or AARS2-related leukoencephalopathy with negative genetic
testing for both CSF1R and AARS2 gene mutations [11, and
personal observation]. Thus, the concept of adult-onset leuko-
encephalopathy with axonal spheroids and pigmented glia
(ALSP), initially introduced by Marotti et al. [6] and further
popularized by Wider et al. [11], is still quite useful. Konno et 
al. [3] make this distinction even more specific by introducing 
the term, CSF1R/AARS2-negative ALSP. It is very likely that
there are other so far unidentified genes in which mutations are 
responsible for clinical and pathologic phenotypes currently
indistinguishable from those seen in CSF1R-related leukoen-
cephalopathy and AARS2-related leukoencephalopathy.
The third and most important reason is that clinical fea-
tures of CSF1R-related leukoencephalopathy are very broad, 
encompassing headaches, seizures, spasticity, rigidity, tremors, 
psychiatric features, dementia, among others, thus leading to 
misdiagnosis or delayed diagnosis. Fortunately, a much wider 
availability of clinical genetic testing at this juncture makes 
Table 1. Current and previously used nomenclature
Current nomenclature Previously used nomenclature
CSFIR-related leukoencephalopathy POLD cases/families
Previously mislabeled HDLS cases/families 
AARS2-related leukoencephalopathy HDLS cases/families
CSF1R/ANRS2-negative ALSP Genetically negative for CSF1R/AARS2 mutation cases/families
CSF1R-related leukoencephalopathy — colony stimulating factor 1 receptor-related leukoencephalopathy; POLD — pigmented orthochromatic leukodystrophy; HDLS — hereditary diffuse leukoencephalo-
pathy with axonal spheroids; AARS2-related leukoencephalopathy — alanyl tRNA synthetase-related leukoencephalopathy; ALSP — adult-onset leukoencephalopathy with axonal spheroids and pigmented glia
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the diagnosis easier and faster as demonstrated in the case 
presented by Żur-Wyrozumska et al. [1]. I congratulate Żur- 
-Wyrozumska et al. for their diagnostic success and for bring-
ing this case to the attention of the readership of the Polish 
Journal of Neurology and Neurosurgery. It is very likely that 
more cases of this disease will be identified in Poland. 
At the present time, CSF1R-related leukoencephalopathy 
is an incurable disease. However, a better understanding of 
the pathophysiology and molecular biology of this illness 
makes development of a halting progression therapy a possi-
bility [4]. In fact, hematopoietic stem cell transplantation has 
already been used to treat several patients (briefly discussed 
in Tipton, et al. [12]).  
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